Compare Adaptive Biotechnologies Corp (ADPT) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs ProShares Ultra Semiconductors — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while ProShares Ultra Semiconductors trades at $90.82. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, ProShares Ultra Semiconductors nearer its low. Which is the better fit depends on your goals.
| ADPT | USD | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $22.37 | $113.53 |
52-Week Low | $10.24 | $37.63 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
USD stock trades at $90.36, up 3.26% with a bearish technical signal from moving averages. The company announced a $0.14 dividend payable June 30, 2026. Recent news highlights institutional interest with JPMorgan Chase increasing its stake by 325% in Q3 2026. Technical indicators show neutral oscillators but bearish momentum with key support at $85 and resistance at $93.
The stock faces headwinds from bearish technical momentum despite recent price gains. Institutional accumulation and dividend payments provide support, but the overall technical picture suggests caution. Semiconductor sector volatility remains a key risk factor for this leveraged ETF.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
